A share price of Avadel Pharmaceuticals plc [AVDL] is currently trading at $13.69, up 1.41%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AVDL shares have gain 7.37% over the last week, with a monthly amount glided 26.29%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Deutsche Bank started tracking the stock with Buy rating on February 11, 2025, and set its price target to $12. On June 12, 2024, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $27 on the stock. Oppenheimer reiterated its Outperform rating and increased its price target to $29 on March 05, 2024. Needham reiterated its recommendation of a Buy and raised its price target to $22 on March 05, 2024. H.C. Wainwright reiterated a Buy rating for this stock on March 05, 2024, and upped its price target to $25. In a note dated February 06, 2024, UBS initiated an Buy rating and provided a target price of $21 on this stock.
Avadel Pharmaceuticals plc experienced fluctuations in its stock price throughout the past year between $6.38 and $16.66. Currently, Wall Street analysts expect the stock to reach $18.6 within the next 12 months. Avadel Pharmaceuticals plc [NASDAQ: AVDL] shares were valued at $13.69 at the most recent close of the market. An investor can expect a potential return of 35.87% based on the average AVDL price forecast.
Analyzing the AVDL fundamentals
Trailing Twelve Months sales for Avadel Pharmaceuticals plc [NASDAQ:AVDL] were 221.07M which represents 64.15% growth. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -0.1%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.36 and Total Capital is -0.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.44 points at the first support level, and at 13.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.89, and for the 2nd resistance point, it is at 14.08.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Avadel Pharmaceuticals plc [NASDAQ:AVDL] is 2.79. Also, the Quick Ratio is 2.38, while the Cash Ratio stands at 1.11. Considering the valuation of this stock, the price to sales ratio is 6.01, the price to book ratio is 14.61.
Transactions by insiders
Recent insider trading involved Palczuk Linda, Director, that happened on Jan 21 ’25 when 5000.0 shares were purchased. Director, Thornton Peter J. completed a deal on Jan 13 ’25 to buy 10000.0 shares. Meanwhile, Director Ende Eric J bought 30000.0 shares on Jan 13 ’25.
